Show Chung Ho
Chairman, SinoPac Financial Holdings.
Currently Chairman of SinoPac Financial Holdings, Mr. Ho was previously Chairman of Yuen Foong Yu (YFY), a banking, paper manufacturing, publishing and technology industry business conglomerate. In addition to TaiGen, YFY has invested in companies with proprietary technologies for monoclonal antibodies, gene chips and agricultural biotechnology. Playing a key role in the recent development of the local biotech industry and one the most respected businessmen in Taiwan, Mr. Ho trained in mechanical engineering with a MS degree from University of Wisconsin and a BS degree from National Cheng Kung University of Taiwan.

Ming-Chu Hsu, Ph.D.
Founder, President, CEO and Chairman of the Board.
Dr. Hsu founded TaiGen in 2001, after successfully building the Biotechnology and Pharmaceutical Research Division of the National Health Research Institutes in Taiwan as its founding director. She was also the leader of the Biotechnology/Pharmaceutical Research Program at the National Science and Technology Program in Taiwan, bringing together 62 academic laboratories to conduct mission-oriented research. Before her return to Taiwan in 1998, Dr. Hsu held the position of Research Director, Oncology and Virology at Hoffmann-La Roche, USA for over 10 years. Prior to that, Dr. Hsu was an assistant professor at Rockefeller University, New York, and a Research Fellow at the California Institute of Technology at Stanford University. Dr. Hsu obtained her Ph.D. degree in biochemistry from the University of Illinois, Urbana-Champaign. Dr. Hsu has extensive experience in establishing both world-class drug discovery teams and clinical development programs.

Michael Steinmetz, Ph.D.
Director
Dr. Steinmetz is the Managing Director of Clarus Ventures. Prior to that, he was the General Partner at MPM Capital until 2005. Prior to joining MPM in 1997 Dr. Steinmetz spent 10 years at Hoffmann-La Roche, holding the position of Vice President, Pre-clinical Research and Development overseeing more than 800 scientists in Nutley, New Jersey, and heading Central Research in Basel, Switzerland. Under his leadership, multiple drug candidates--including recombinant proteins, antibodies and small molecules--were discovered and moved into clinical trials. He also conceptualized and managed many of Roche's research-stage alliances including the company's first investment in genomics (Millennium) as well as collaborations with Incyte and Caliper. An accomplished scientist with over 130 publications in peer-reviewed journals, Dr. Steinmetz obtained his doctoral degree from the University of Munich and held positions at the California Institute of Technology and the Basel Institute for Immunology prior to joining Roche.

Jack Lief
Director
Mr. Lief is a co-founder of Arena and has served as the President and CEO since April 1997. From 1995 until April 1997, Mr. Lief served as an advisor and consultant to numerous biopharmaceutical organizations. From 1989 to 1994, he served as a Senior Vice President for Corporate Development and Security of Cephalon. From 1983 to 1989, Mr. Lief served as the Director of Business Development and Strategic Planning for Alpha Therapeutic Corporation. In 1972 Mr. Lief joined Abbott Laboratories where he served until 1983, most recently as the Head of International Marketing Research. Mr. Lief holds a B.A. from Rutgers University and a M.S. in psychology (experimental and neurobiology) from Lehigh University.

Steve Lee
Director
Mr. Lee is the Special Assistant to the Chairman, China Steel Corporation. Before that, he was the President and CEO of TaiAn Technologies Corporation, a healthcare venture capital firm, until 2005. Prior to this position, Mr. Lee was the Executive Vice President and then the President of Taisil Electronic Materials Corporation, a company which produces silicon wafers for the semiconductor industry. Mr. Lee has a long and distinguished career at China Steel Corporation and represents that company on the boards of both TaiGen Biotechnology and Genmont Biotech. Mr. Lee holds a MBA from the Sloan Fellows Program at the Massachusetts Institute of Technology.

William R. Keller
Director
Mr. Keller spent more than 30 years of his career at Roche. Prior to joining the board of directors at TaiGen Biotechnology, he was the General Manager of Roche China from 1992 to 2003. Under his leadership, Roche became one of the leading pharmaceutical companies in China. Mr. Keller first joined Roche in 1972, being promoted to the position of Deputy General Manager of Roche Brazil and later, General Manager of Roche Columbia, before becoming the General Manager of Roche China.

Top